Atopic Dermatitis Clinical Trials

54 studies are recruiting for atopic dermatitis in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Topical Treatment for Atopic Dermatitis

   Medication adherence is a poorly studied phenomenon that challenges both patients and physicians. 50% of individuals with chronic disease are not adherent to their medication regimen. Within the United States, non-adherence to medical treatment leads to approximately $100 billion in hospital admiss…

   Stage

   Not phased

   Ages

   9 and older

   Site

   Wake Forest University Health Sciences, Winston-Salem, North Carolina

   Run by

   Wake Forest University Health Sciences

   See if you can join NCT06244212 on ClinicalTrials.gov

2. FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

   The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in p…

   Stage

   Phase 1

   Ages

   18 to 70

   Site

   Anaheim Clinical Trials, LLC, Anaheim, California

   Locations

   5 in total

   Run by

   Pfizer

   See if you can join NCT06564389 on ClinicalTrials.gov

3. Skin Microbial Ecology in Atopic Dermatitis

   Everybody's skin has bacteria that normally lives on it. Previous research has shown that people with eczema (or atopic dermatitis [AD]) have much higher concentrations of a certain bacteria (S. aureus), especially when their disease is active but little is known about the role that this bacteria p…

   Stage

   Not phased

   Ages

   13 and older

   Site

   University of Rochester Medical Center, Rochester, New York

   Run by

   University of Rochester

   See if you can join NCT04170244 on ClinicalTrials.gov

4. Sodium in the Skin and Atopic Dermatitis

   The goal of this observational study is to understand factors associated with skin sodium storage in healthy adults and people with atopic dermatitis ages 50 and above. The study is designed to test whether diet and skin barrier function are associated with skin sodium concentration and whether ski…

   Stage

   Not phased

   Ages

   50 and older

   Site

   San Francisco VA Medical Center, San Francisco, California

   Locations

   2 in total

   Run by

   University of California, San Francisco

   See if you can join NCT06998446 on ClinicalTrials.gov

5. A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

   The purpose of this trial is to test whether treatment with tralokinumab (administered subcutaneous injections [SC]) in combination with topical corticosteroids (TCS) is safe and effective to treat moderate-to-severe atopic dermatitis (AD) in children and infants. This will be judged by a range of …

   Stage

   Phase 3

   Ages

   0 to 11

   Site

   Leo Pharma Investigational site, Birmingham, Alabama

   Locations

   72 in total

   Run by

   LEO Pharma

   See if you can join NCT06311682 on ClinicalTrials.gov

6. A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

   Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy an…

   Stage

   Phase 3

   Ages

   18 to 63

   Site

   Cahaba Dermatology & Skin Health Center /ID# 263855, Birmingham, Alabama

   Locations

   128 in total

   Run by

   AbbVie

   See if you can join NCT06389136 on ClinicalTrials.gov

7. Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

   This is a Phase 1b, randomized, placebo/vehicle-controlled, double-blinded, multi-center trial. It is designed to assess the safety and efficacy of S. hominis A9 (ShA9) topical application as a treatment for atopic dermatitis (AD). The trial will enroll adults and pediatric participants with atopic…

   Stage

   Phase 1

   Ages

   6 and older

   Site

   University of California, San Diego: Dermatology Clinical Trials Unit, San Diego, California

   Locations

   8 in total

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT06504160 on ClinicalTrials.gov

8. CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry

   Prospective observational registry for an adolescent cohort with AD under the care of a dermatology provider. Approximately 1500 subjects and 75 clinical sites in North America and select European countries will be recruited to participate with no defined upper limit for either target.

   Stage

   Not phased

   Ages

   10 to 15

   Site

   CorEvitas, LLC, Waltham, Massachusetts

   Run by

   CorEvitas

   See if you can join NCT06238765 on ClinicalTrials.gov

9. Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

   This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy, pharmacokinetics, and Safety of repeat subcutaneous doses of FB825 in adults with moderate-to-severe atopic dermatitis.

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   First OC Dermatology, Fountain Valley, California

   Locations

   16 in total

   Run by

   Oneness Biotech Co., Ltd.

   See if you can join NCT06397911 on ClinicalTrials.gov

10. Molecular Signatures of Cutaneous Dupilumab Response

    This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.

    Stage

    Phase 4

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    University of California, San Francisco

    See if you can join NCT05858619 on ClinicalTrials.gov

11. Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

    This protocol is primarily looking to see if the IL-4Ra R576 polymorphism is associated with increased clinical, immunological and microbial markers of disease activity in patients with Atopic dermatitis.

    Stage

    Not phased

    Ages

    6 to 65

    Site

    Boston Children's Hospital, Boston, Massachusetts

    Run by

    Boston Children's Hospital

    See if you can join NCT04455906 on ClinicalTrials.gov

12. A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

    The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction. This study is seeking participants who: * are 18 years of age or more. …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Allervie Clinical Research, Birmingham, Alabama

    Locations

    98 in total

    Run by

    Pfizer

    See if you can join NCT05995964 on ClinicalTrials.gov

13. Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

    Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old

    Stage

    Phase 4

    Ages

    6 to 17

    Site

    Lurie Children's Hospital/Northwestern University, Chicago, Illinois

    Run by

    Northwestern University

    See if you can join NCT05042258 on ClinicalTrials.gov

14. Dupilumab De-escalation in Pediatric Atopic Dermatitis

    This is a pilot investigator-blinded, randomized clinical trial to assess the feasibility of dupilumab treatment discontinuation or dose-reduction in children aged 1-17 years who have achieved sustained atopic dermatitis (AD) control on dupilumab.

    Stage

    Phase 4

    Ages

    1 to 17

    Site

    Johns Hopkins Univerisity, Baltimore, Maryland

    Run by

    Johns Hopkins University

    See if you can join NCT06116526 on ClinicalTrials.gov

15. Registry for Systemic Eczema Treatments

    The Registry for Systemic Eczema Therapies (RESET) registry is a database and biospecimen repository for patients with pediatric-onset atopic dermatitis (AD) who have used or will initiate any systemic treatment(s) for AD. The goal of the registry is to enable more efficient research recruitment an…

    Stage

    Not phased

    Ages

    1 to 26

    Site

    Johns Hopkins University, Baltimore, Maryland

    Run by

    Johns Hopkins University

    See if you can join NCT06136767 on ClinicalTrials.gov

16. Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

    The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.

    Stage

    Not phased

    Ages

    12 and older

    Site

    Galdrma Investigational Site - 7077, Phoenix, Arizona

    Locations

    108 in total

    Run by

    Galderma R&D

    See if you can join NCT06988605 on ClinicalTrials.gov

17. Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

    The main purpose of this study is to see how well different doses of soquelitinib work in participants with atopic dermatitis (AD) as compared to a placebo (pill with no medicine in it). To check this, the study doctors will examine participants' skin regularly to track how their AD changes during …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Corvus Clinical Trials, South San Francisco, California

    Run by

    Corvus Pharmaceuticals, Inc.

    See if you can join NCT07441395 on ClinicalTrials.gov

18. Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome

    This is a single-center, open-label, basket phase 2b trial that will enroll Down Syndrome (DS) participants with at least one inflammatory skin condition (Atopic Dermatitis (AD) and/or Alopecia Areata (AA)). Patients will receive Abrocitinib 100 mg daily for 12 weeks. Responders (defined as achievi…

    Stage

    Phase 2

    Ages

    12 and older

    Site

    Icahn School of Medicine at Mount Sinai, New York, New York

    Run by

    Icahn School of Medicine at Mount Sinai

    See if you can join NCT07242638 on ClinicalTrials.gov

19. Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

    This is a tissue, urine, and blood banking protocol for cutaneous t-cell lymphoma (CTCL), eczema, and atopic dermatitis patients for current and future research.

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

    Run by

    University of Pittsburgh

    See if you can join NCT00177268 on ClinicalTrials.gov

20. Study to Compare Maternal, Fetal, and Infant Outcomes of Women With Mild to Moderate Atopic Dermatitis Exposed to Ruxolitinib Cream During Pregnancy With an Unexposed Control Population

    This observational (enrollment into the registry while the pregnancy is ongoing) study is being conducted to compare the frequency of major congenital malformation (MCM)s among infants of women exposed to ruxolitinib cream during pregnancy with infants of women not exposed to ruxolitinib cream duri…

    Stage

    Not phased

    Ages

    15 to 50

    Site

    Syneos Health (remote site), Morrisville, North Carolina

    Run by

    Incyte Corporation

    See if you can join NCT06259669 on ClinicalTrials.gov

21. An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis

    This study is to assess infant outcomes of women with AD who were exposed to ruxolitinib cream during pregnancy compared with a control cohort of women with AD who were exposed to a topical corticosteroid (TCS) during pregnancy.

    Stage

    Not phased

    Ages

    14 and older

    Site

    Syneos Health (remote site), Morrisville, North Carolina

    Run by

    Incyte Corporation

    See if you can join NCT06627335 on ClinicalTrials.gov

22. A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring

    The purpose of this observational study is to learn about the safety of abrocitinib (CIBINQO) in pregnant women and the offspring. The study is seeking participants who: * Are currently or recently pregnant * Receive at least one dose of CIBINQO at any time during pregnancy or prior to pregnancy OR…

    Stage

    Not phased

    Ages

    0 and older

    Site

    Pfizer, New York, New York

    Run by

    Pfizer

    See if you can join NCT05721937 on ClinicalTrials.gov

23. Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project

    This study will explore potential links between atopic dermatitis and food allergy. This information will be useful to determine atopic dermatitis and food allergy share unique biochemical or genetic identifiers useful for diagnosing and treatments in the future. This is a mechanistic study consist…

    Stage

    Not phased

    Ages

    10 to 55

    Site

    University of Michigan, Ann Arbor, Michigan

    Run by

    University of Michigan

    See if you can join NCT06300697 on ClinicalTrials.gov

24. Ethnic Differences in Mechanisms of Action of Dupilumab

    Previous research has shown that Asian and African Americans are more likely to develop atopic dermatitis (AD) than their Caucasian counterparts. However, limited information is known about AD in Asian and African American populations because most molecular studies have focused on Caucasians with A…

    Stage

    Phase 4

    Ages

    18 and older

    Site

    University of Michigan, Ann Arbor, Michigan

    Run by

    University of Michigan

    See if you can join NCT05268107 on ClinicalTrials.gov

25. A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis

    The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of a single and multiple SC dose of BxC-I17e in patients with moderate to severe atopic dermatitis (AD)

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Arkansas Research Trials, North Little Rock, Arkansas

    Locations

    3 in total

    Run by

    Brexogen Inc.

    See if you can join NCT06055361 on ClinicalTrials.gov